

Jason Aldred, MD FAAN

Selkirk Neurology, PLLC
Univ of Washington
WSU ESF COM
610 S Sherman St Ste 201
Spokane, WA 99202

Telephone: 509-475-0885
Fax: 509-795-0895
jaldred@selkirkneurology.com
Updated August 18th, 2025

EDUCATION

2007-2009	Research Training: Human Investigators Program Oregon Health And Science University - Portland, OR
2007-2009	PADRECC Fellowship - Movement Disorders Oregon Health And Science University - Portland, OR
2005-2006	Chief Resident Neurology
2004-2006	Neurology Residency Oregon Health And Science University - Portland, OR
2003-2004	Neurology Internship Oregon Health And Science University - Portland, OR
1999-2003	Medical School University of Tennessee College of Medicine - Memphis, TN
1996-1999	BA College Scholars: Ancient Greek, Latin and Biochemistry The University of Tennessee - Knoxville, TN

UNIVERSITY APPOINTMENTS

2019-2025	Clinical Assistant Professor Elson S. Floyd College of Medicine, Washington State University
2025-Current	Clinical Professor Elson S. Floyd College of Medicine, Washington State University
2014-2021	Clinical Assistant Professor University of Washington, Department of Neurology
2021-Current	Clinical Associate Professor University of Washington, Department of Neurology

CLINICAL WORK HISTORY

2018-Current	Owner: Selkirk Neurology, PLLC, Spokane, WA
2017-Current	Owner: Inland Northwest Research, LLC, Spokane, WA
2016-Current	Owner: Arete Neuroscience, Spokane, WA
2022-Current	Director, Huntington Disease Center of Excellence Partner Site Selkirk Neurology, Spokane WA
2014-2018	Co-Owner, CEO Northwest Neurological, PLLC, Spokane, WA

2015-2017	Principal Investigator Premier Clinical Research, Spokane, WA
2009-2014	Director of Parkinson's and Movement Disorder Center Gundersen Health System
2011-2014	Chairman Department of Neurology Gundersen Health System
2007-2009	PADRECC Movement Disorders Fellow Oregon Health And Science University , Portland, OR
2007-2009	Stroke Team Oregon Health And Science University, Portland, OR
2006-2007	Chief Neurology Resident Oregon Health And Science University, Portland, OR
2003-2007	Neurology Resident

TEACHING ACTIVITIES

2025- Current	Washington State University, Elson S. Floyd College of Medicine- Instructor for neurological examination
2023-Current	Neurology Rotation- Psychiatry Residency Providence Sacred Heart Medical Center
2022-Current	Neurology Rotation- St Lukes Medical Center Physical and Rehabilitation Medicine Residency
2021-2022	Neurology Rotation Providence Internal Medicine Residency- Spokane
2014- Current	University of Washington- Instructor for movement disorders section
2014- Current	University of Washington- Neurology Clerkship Month
2019-Current	Washington State University, Elson S. Floyd College of Medicine- Neurology Clerkship

LICENSURE

2014-Current	State of Washington, Unlimited License
2016-Current	State of Montana, Unlimited License
2018-Current	State of Idaho, Unlimited License
2023-Current	State of Arizona, Unlimited License

BOARD CERTIFICATION

American Board of Psychiatry & Neurology
 Certification 2008
 Recertified 2020
 Recertified 2024

Vascular Neurology- American Board of Psychiatry & Neurology
 Certification 2009
 Recertification 2021
 Recertification 2024

PROFESSIONAL EXPERIENCE

Chair, Inland Northwest Movement Disorders Society
Member, American Academy of Neurology: Parkinson Disease Measurement Set Working Group
Member, Movement Disorders Society Telemedicine Working Group
Member, Board of Directors Parkinson Resource Center Spokane Washington
Chairman, Gundersen Lutheran Health System Department of Neurology
Member, Board of Directors, Minnesota Chapter, National Parkinson Association
Director, Gundersen Lutheran National Parkinson Foundation Care Center
President Elect, Washington State Neurological Society

ACTIVITIES

2021-2025	Washington State Neurological Society, Board Member
2025-Current	Washington State Neurological Society, President Elect
2023-Current	American Academy of Electrodiagnostic Medicine
2019-Current	Huntington Study Group
2009-Current	Parkinson Study Group
2006-Current	Movement Disorder Society
2004-Current	American Academy of Neurology

HONORS AND AWARDS

2015	Fellow of the American Academy of Neurology
2007	Resident Scholarship to Annual AAN Meeting
2002	Dr John H and Marjorie Burkhart Medical Education Scholarship
2001	Roan Scholarship Award for Medicine
1998	Phi Beta Kappa
1997	Haines-Morris Award for Scholarship in Classics
1997	Beta Sigma Phi, National Honors Society for Classical Studies
1995	Eagle Scout

PUBLICATIONS

Pahwa R, Aldred J, et al. Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials. *Neurol Ther.* 2025 Oct.

Pahwa R, Molho E, et al. Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial. *Neurol Ther.* 2025 Aug;14(4):1553-1567.

Aldred J, Bouchard M, et al. Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease. *Mov Disord Clin Pract*. 2025 Jul 30.

Aldred JL, Zesiewicz T, et al. Sustained Therapeutic Benefits Using Image-Guided Programming at Activation of Deep Brain Stimulation for Parkinson's Disease. *Mov Disord Clin Pract*. 2025 Jun 5.

Soileau M, Kumar R, Parab A, Brion T, White K, Yan CH, Shah MB, Kukreja P, Facheris MF, Shewale A, Aldred J. Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease. *J Neurol*. 2025 May 22;272(6):416.

Ellenbogen AL, Poewe W, et al. Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study. *Parkinsonism Relat Disord*. 2025 Mar;132:107293.

Westenberger, A, Aldred J, et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study. *Brain*. 2024 Aug 1;147(8):2652-2667.

Fung V, Aldred J, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion for the Treatment of Motor Fluctuations in Parkinson's Disease: Considerations for Initiation and Maintenance. 2024. *Clin Park Relat Disord*. 2024 Feb 10;10:100239.

Aldred J, Freire-Alvarez E, et al. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. *Neurol Ther*. 2023 Dec; 12 (6): 1959-1960.

Aldred, J, Freire-Alvarez, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. *Neurol Ther*. 2023 Dec; 12 (6):1937-1958.

Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. *Lancet Neurol*. 2022 Dec;21(12):1099- 1109.

Lang AE, Siderowf AD, Macklin EA, Poewe W, Aldred, J. et al. T; SPARK Investigators. Trial of Cinpanemab in Early Parkinson's Disease. *N Engl J Med*. 2022 Aug 4;387(5):408-420.

Kovács N, Aldred J, et al. Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. *J Parkinsons Dis*. 2022;12(3):917-926.

Jennings D, Aldred J, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. *Sci Transl Med*. 2022 Jun 8;14(648)

Pahwa R, Aldred J, et al. SH. Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses. *Neurol Ther.* 2022 Jun;11(2):711-723.

Simuni T, Merchant K, Aldred J et al. Parkinson Study Group NILO-PD Investigators and Collaborators. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol.* 2021 Mar 1;78(3):312-320.

Schwarzschild MA, Ascherio A, Gauger L, Aldred J, Bixby M, Parkinson Study Group SURE-PD3 Investigators et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. *JAMA.* 2021 Sep 14;326(10):926-939

Aldred J, Anca-Herschkovitsch M, et al.. DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. *Mov Disord Clin Pract.* 2021 Sep 12;8(7):1061-1074.

Beck CA, Beran DB, Biglan KM, Boyd CM, et al. Connect.Parkinson Investigators. National randomized controlled trial of virtual house calls for Parkinson disease. *Neurology.* 2017 Sep 12;89(11):1152-1161

Hassan A, Mari Z, Aldred J et al. International Telemedicine Study Group. Global Survey on Telemedicine Utilization for Movement Disorders During the COVID-19 Pandemic. *Mov Disord.* 2020 Oct;35(10):1701-1711

DeKarske D, Aldred, JL et al. An Open Label, 8 Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.[published online ahead of print, 2020 Aug 5. *Parkinsons Dis.* 2020;10.

Aldred J, Wingett D, Martin BA, et al. Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients. *Fluids Barriers CNS.* 2020 Jan 21;17(1):4.

Brys, Miroslav, Aldred, J, et al. Randomized Phase 1 Clinical Trial of Anti-Alpha- Synuclein Antibody BII054. *Mov Disord,* 2019 Aug; 34(8): 1154-1163

Antonini A, Aldred et al. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review. *Adv Ther.* 2021 Jun;38(6):2854-2890.

Aldred J, Anca-Herschkovitsch M et al. Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. *Neurodegener Dis Manag.* 2020 Oct;10(5):309-323.

Burack, M, Aldred, J et al. DUOPA is an Excellent Alternative Treatment but with Some Caveats. *Mov Disord Clin Pract.* 2019 Mar 27;6(4): 336-337.

Carlson, JD, Aldred, J et al. Deep Brain Stimulation Generator Replacement in End- Stage Parkinson Disease. *World Neurosurg.* 2019 Aug; 128 e683-e687.

Burack M, Aldred J, et al.. Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. *Mov Disord Clin Pract.* 2018 Jun 27;5(4):383-393..

Dorsey ER, Aldred J, et al. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. *Telemed JE health.* 2016.

Achey M, Aldred J, et al. The past, present, and future of telemedicine for Parkinson's disease. *Movement Disorders.* 871-83, 29,7.2014.

Pandey S, Aldred J, et al. Post-Traumatic Shoulder Movement Disorders: A Challenging Differential Diagnosis Between Organic and Functional. *Mvmt Dis Clin Prac.* 102-105, 1, 2.2014.

Brod L, Aldred J, Nutt J. Are High Doses of Carbidopa a Concern? A Randomized Clinical Trial in Parkinson's Disease. *Movement Disorders.* 2012 May; 27(6):750-3. *Movement Disorders.* 1-11, 4.2018.

Beck Ca, Aldred J. et al. National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease. *Neurology.* 1152-1161, 89, 11. 2017.

POSTERS

2025. Bergquist, F, Aldred, J et al. Sustained Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa in Parkinson's Disease: 96-week Primary Treatment Period Results from an Ongoing Open-label Extension Study. American Academy of Neurology. San Diego, CA

2024. Aldred J, et al. Clinical and Safety Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control – Real-World, USA Experience. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Philadelphia, PA

2024. Fung V, Aldredk J. et al, Long-Term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson's Disease: Interim Results From an Ongoing Open-Label Extension. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Philadelphia, PA

2024. Okun M, Aldred J, et al. Assessment of Image-Guided Programming (IGP) in Bilateral STN and GPi Deep Brain Stimulation on Programming Time and Setting Outcomes. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Philadelphia, PA

2024. Bergquist F, Aldred J, et al. Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson's Disease. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Philadelphia, PA

2024. Improvement of motor and non-motor symptoms with bezistermin (NE3107) adjunctive to carbidopa/levodopa in patients with Parkinson's disease: A phase 2A, placebo-controlled study. Advanced Therapeutics for Parkinson disease and related disorders. Washington, DC.

2024: Aldred J, et al. Assessment of Image-guided Programming (IGP) on Bilateral STN and GPi Deep Brain Stimulation Programming Time. American Academy Of Neurology. Denver, Colorado. USA.

2024: Okun M, Aldred et al. Real-world Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control: USA Experience. American Academy Of Neurology. Denver, Colorado. USA.

2024: Metman V, Aldred J. Quality of Life Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa in People with Parkinson's. American Academy Of Neurology. Denver, Colorado. USA.

2024: Soileau M, Aldred J, et al. Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson's Disease: A Patient Experience Study. American Academy Of Neurology. Denver, Colorado. USA.

2024: Fung V, Aldred J. et al. Long-term Safety and Tolerability of Foslevodopa /Foscarbidopa for Treatment of Motor Fluctuations in Parkinson's Disease. American Academy Of Neurology. Denver, Colorado. USA.

2023: Aldred J., et al. Rapid Onset ON-time and Improvement in Motor State Stability in aPD Patients after Treatment with Continuous Subcutaneous Foslevodopa/Foscarbidopa. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Copenhagen, Denmark.

2023: Aldred J, Zesiewicz T, et al. Image Guided Programming Reduces Initial DBS Programming Time. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Copenhagen, Denmark.

2023: Aldred J, Fahd Amjad F. A Retrospective Study Evaluation the Use of Anti-Parkinsonian Medications in Patients with Advanced Parkinson's Disease Who Are Treated with Levodopa-Carbidopa Intestinal Gel and Deep Brain Stimulation: The PD-DUAL Study. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Copenhagen, Denmark.

2023: Aldred, J, Henricksen T. et al Efficacy and Safety of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion Administered as Monotherapy in Patients with Parkinson Disease. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Copenhagen, Denmark.

2023. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Philadelphia, PA

2022: Hauser, R., Aldred, J et al. Duration of Continuous "Good On" Intervals and Number of Motor Fluctuations: IPX203 (Extended- Release Carbidopa-Levodopa) Vs Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients with Motor Fluctuations. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Madrid, Spain.

2022: Soileau, M., Aldred, J. et al. Subcutaneous Foslevodopa/Foscarbidopa in Patient's with Advanced Parkinson's Disease: Results from a Randomized, Double- Blind, Double-Dummy Phase 3 Trial. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Madrid, Spain. PLATFORM PRESENTATION.

2022: Soileau, M., Aldred, J. et al. Impact of Foslevodopa/Foscarbidopa on Key Clinical and Patient-Reported Outcomes in Patients with aPD: Responder Analysis of Two Phase 3 Clinical Trials. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Madrid, Spain.

2022: Pahwa, R., Aldred, J., et al. Rapid Onset of Good ON-Time and Improvement in Motor-State Stability in aPD Patients after Treatment with Continuous SubCutaneous Foslevodopa/Foscarbidopa. International Congress of Parkinson's Disease and Movement Disorders Annual Meeting. Madrid, Spain.

2022: Aldred, J. et al. Visualization Tool for DBS Programming Used with a Multiple- Source, Constant-Current System Reduces Initial Programming Time. International Neuromodulation Society- 15th World Congress. Barcelona, Spain.

2022: Chaudhuri, K., Aldred, J. et al. Levodopa-Carbidopa Intestinal Gel Improves Long-Term Parkinson's Disease Symptoms: Final Analysis of the DUOGLOBE study. The 8th Congress of the European Academy of Neurology. Vienna, Austria.

2022: Chaudhuri, K., Aldred, J. et al. Long-term Motor and Non-Motor Symptom Benefits in Patients With Advanced Parkinson's Disease Treated With Levodopa- Carbidopa Intestinal Gel: Final Analysis of the 36-Month DUOGLOBE Real-world Multinational Observational Study. International Association of Parkinsonism and Related Disorders- 27th World Congress. Virtual.

2021: Aldred, J et al. Utilization of New Visualization Software for Deep Brain Stimulation Programming Using a Multiple-Source, Constant Rechargeable System. American Academy of Neurology Annual Meeting. Prague, Czech Republic.

2021: Aldred, J. et al. Programming Time Using a Novel Visualization Tool in a Deep Brain Stimulation Registry. American Academy of Neurology Annual Meeting. Virtual.

2020: Jennings, D., Aldred, J. et al. Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at Dose Levels Demonstrating LRRK2 Inhibition in Parkinson's Disease Patients with and Without LRRK2 Mutations. International Parkinson and Movement Disorder Society (MDS). Virtual.

2019: Standaert D, Aldred J, et al. Levodopa-Carbidopa Intestinal Gel for the Treatment of Motor Fluctuations and Dyskinesia in Patients with Advanced Parkinson's Disease in a "Real World" Setting: Results of an Interim Analysis of the Multinational Observational Long-Term Study Duoglobe. XXIV World Congress of Neurology. Dubai, United Arab Emirates.

2019: Guskey M, Aldred J et al. Open-Label Study of Pimavanserin in Patients with Comorbid Parkinson's Disease and Depression. Neuroscience Education Institute Congress. Colorado Springs, CO USA

2019: Guenther, J, Aldred, J et al. Asynchronous Telehealth Consultations for Movement Disorders in Africa. International Congress of Parkinson's Disease and Movement Disorder Society. Toronto, Canada.

2017: Mark S, Aldred J, et al. Motor effects and safety of 1PX203, an investigational extended-release formulation of carbidopa- levodopa, in advanced Parkinson's disease: A single-dose study .International Congress of Parkinson's Disease and Movement Disorders Society. Vancouver, BC.

2016: Aldred, J. Levodopa Carbidopa Infusion Gel for Very Advanced Parkinson Disease. American Academy of Neurology Annual Meeting. Vancouver, Canada.

2015: Achey MA, Connect. Parkinson Investigators and Coordinators. A Randomized Controlled Trial of Telemedicine for Parkinson Disease (Connect.Parkinson) in the United States: Interim Assessment of Investigator and Participant Experiences.

2013: Kemdt T, Aldred J, Medication Use and In-Hospital Complications for Patients with Parkinson's Disease: A Retrospective Review. World Parkinson Congress. Geneva, Switzerland.

2009: Aldred, J and Nutt, J. Hyperkinetic Shoulder Movement Disorder Associated with Ehlers-Danlos Syndrome. American Academy of Neurology Annual Meeting. Seattle, WA USA.

2008: Aldred J, Chung K, et al. Efficacy of Donepezil for Tic Reduction. International Movement Disorders Society Congress. Chicago, IL USA.

2009: Aldred, J and Nutt, J. Hyperkinetic Shoulder Movement Disorder Associated with Ehlers-Danlos Syndrome. American Academy of Neurology Annual Meeting. Seattle, WA USA.

REVIEWER

Journal - Parkinson's Disease and Related Disorders

Journal - Movement Disorders in Clinical Practice

CLINICAL RESEARCH ACTIVITY

2025: Principal Investigator. A Phase 1/2 Dose-Escalation Trial to Evaluate Safety, Tolerability, and Efficacy of a Single Dose of CAP-003 Gene Therapy Administered to Patients with Parkinson's Disease with GBA1 Gene Mutation (PD-GBA).

2025: Principal Investigator. Double-blind, Randomized Controlled Trial to Demonstrate Efficacy of Celeste Specialized Phototherapy in Treating Symptoms of Parkinson's Disease (Pro00075683).

2025: Principal Investigator. A Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Co-Administration of VMA-1001 ER and VMA-1002 ER in Healthy Adult Volunteers and Adults with Isolated Dystonia.

2024: A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy.

2024: Principal Investigator. Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy.

2024: Principal Investigator. A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD).

2024: Principal Investigator. Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients with Motor Complications.

2024: Principal Investigator. A Global Real-World Study on the long-term effectiveness of ABBV-951 in Advanced Parkinson's Disease in routine clinical practice.

2024: Principal Investigator. A Randomized, Double Blind, Placebo Controlled, Phase 1B Study of the NLRP3 Inhibitor VENT 02 in Patients with Mild to Moderate Parkinson's Disease.

2024: Principal Investigator. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson's Disease.

2024: Principal Investigator. A Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial (RCT) and an Open Label Extension (OLE) Study.

2024: Principal Investigator. interventional open-label, exploratory study, investigating the safety, tolerability, pharmacokinetics, and efficacy of Lu AF28996 in patients with Parkinson's Disease.

2023: Principal Investigator- A Phase 2, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of BIA 28-6156 in Subjects with Parkinson's Disease with a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene.

2023: Principal Investigator- A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due Parkinson's Disease. TI-214-2023

2023: Principal Investigator- A Multicenter phase 2, double-blind, placebo controlled, randomized, parallel-group study to evaluate the efficacy, safety, tolerability, and

pharmacokinetics of UCB0022 in study participants with advanced Parkinson disease.
Atlantis PD0060

2023: Principal Investigator- Interventional, open-label, exploratory study, investigating the safety, tolerability, pharmacokinetics, and efficacy of Lu AF28996 in patients with Parkinson's disease

2023: Principal Investigator- A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy" TV56286-NDG-20039

2023: Principal Investigator- PhotoPharmics, Inc."LightPD": "Double-blind, Randomized Controlled Trial to Demonstrate Efficacy of Celeste® Specialized Phototherapy in Treating Symptoms of Parkinson's Disease." CT2401

2023: Principal Investigator- A Phase 2, Randomized, Double Blind, Placebo Controlled Dose Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Patients with Prodromal and Early Manifest Huntington's Disease.

2023: Principal Investigator- An Open Label Study of the Long Term Safety and Tolerability of Sage-324 in Participants with Essential Tremor. Sage.

2023: Principal Investigator- A Phase 3, Multicenter, Open-Label Safety Study to Evaluate the Long Term Safety and Tolerability of Sage-718 in Participants with Huntington's Disease. Sage.

2023: Principal Investigator- A Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial and an Open Label Extension Study. Scion.

2022: Principal Investigator -A 6-Month Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients with Early Parkinson's Disease.

2022: Principal Investigator- A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated with Carbidopa/Levodopa and NE3107.

2022: Principal Investigator- A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington's Disease.

2022: Principal investigator- A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy. Takeda.

2022: Principal Investigator - A Study to Evaluate NYX-458 in Subjects with Mild Cognitive Impairment or Mild Dementia Associated with Parkinson's Disease, or Prodromal or Manifest Lewy Body Dementia. Aptinyx.

2022: Principal Investigator- A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants with Parkinson's Disease and Pathogenic LRRK2 Variants. Biogen.

2022: Principal Investigator - A Phase 2b, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson's Disease. Biogen.

2022: Principal Investigator - A Randomized, Double Blind, Placebo Controlled Phase 2B Study Evaluating the Efficacy of Mesdopetam on Daily On Time Without Troublesome Dyskinesia in Patients with Parkinson's Disease. IRL.

2021: Principal Investigator - A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies. Athira.

2021: Principal Investigator - A Double Blind, Placebo Controlled Randomized 18 Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease. UCB.

2021: Principal Investigator - A Phase 2 Clinical Trial Evaluation the Efficacy, Safety and Tolerability and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor. Praxis.

2021: Principal Investigator - A Phase 2, Randomized, Double-Blind, Placebo- Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults with Essential Tremor. Praxis.

2021: Principal Investigator - A Phase 1/2, Two-part, Open-Label Dose-Escalation and Double-Blind, Placebo-Controlled Dose-Expansion Study with an Open- Label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis. Atara

2021: Principal Investigator - A Pilot, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate Safety and Daytime Sedation in Subjects with Parkinson's Disease with Neuropsychiatric Symptoms Treated with Pimavanserin or Low-Dose Quetiapine.

2021: Principal Investigator - LRRK2-Rostock International Parkinson's Disease Program. An International, Multicenter, Epidemiological Observational Study.

2020: Principal Investigator- A Phase 1, Randomized, Placebo-Controlled Study of the Safety and tolerability of multiple ascending doses of MEDI1341 in subjects with Parkinson's Disease AstraZeneca

2020: Principal Investigator- A Randomized, Double-blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Abbvie

2020: Principal Investigator-A Phase IIB, Randomized, Double-blind, Placebo- controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Roche

2020: Principal Investigator- A Phase 2 Study to Evaluate oral TAK-071 in Parkinson Disease Patients with Cognitive Impairment and Elevated Risk of Fall. Takeda

2020: Principal Investigator- A Prospective, randomized, double-blind, placebo- controlled, parallel-group trial with an open-label period to investigate the efficacy and safety of NT 201 in the unilateral and bilateral treatment of essential tremor of the upper limb Merz

2020: Principal Investigator- A Validation Study to Assess the Validity, Measurement Responsiveness, & Reliability of the Parkinson's Disease Functional Impacts Digital Instrument (PD-FIDI) in Patients with Parkinson's Disease (PD) with or without Glucocerebrosidase (GBA) Mutations. Sanofi

2020: Principal Investigator- A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor. Sage Therapeutics.

2019: Principal Investigator- A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Immunogenicity -0805 in Patient's with Parkinson's Disease. Abbvie

2019: Principal Investigator- A Phase 2, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of Da.xibotulinumtoxin A for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury Revance.

2019: Principal Investigator-A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenzaine for the Treatment of Chorea Associated with Huntington's Disease Neurocrine

2019: Principal Investigator- A Phase 1 Multiple-Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults with Parkinson's Disease Biogen

2019: Principal Investigator- A 52 Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of 24 Hour Daily Exposure of Continuous, Subcutaneous Infusion of ABBV-951 in Subjects with Parkinson's Disease Abbvie

2019: Principal Investigator - An Evaluation of Oral Anti-Parkinsonian Medication use in Patients with Advanced Parkinson's Disease with History of Deep Brain Stimulation (DBS) and being treated with Carbidopa Levodopa Enteral Suspension (CLES) Abbvie

2019: Principal Investigator-A Registry of Deep Brain Stimulation with the VERCISE system Boston Scientific

2019:A Phase 1B Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL201 in Subjects with Parkinson's Disease

2019: Principal Investigator- A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of K0706 in Subjects with Early Parkinson's Disease Sun-Pharma

2019: Sub-Investigator- A Double-Blind, Placebo-Controlled, 16 Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies EIP Pharma

2019: Principal Investigator- A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patient's with Parkinson's Disease Abbvie

2019: Principal Investigator- A Phase 2, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of Daxibotulinumtoxin A for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury Revance

2019: Principal Investigator-A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenzaine for the Treatment of Chorea Associated with Huntington's Disease Neurocrine

2019: Principal Investigator- A 52 Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of 24 Hour Daily Exposure of Continuous, Subcutaneous Infusion of ABBV-951 in Subjects with Parkinson's Disease Abbvie

2019: Principal Investigator - An Evaluation of Oral Anti-Parkinsonian Medication use in Patients with Advanced Parkinson's Disease with History of Deep Brain Stimulation (DBS) and being treated with Carbidopa Levodopa Enteral Suspension (CLES) Abbvie

2019: Principal Investigator-A Registry of Deep Brain Stimulation with the VERCISE system Boston Scientific

2019: Principal Investigator- ROPAD LRRK2 Rostock International Parkinson's Disease Program, An International, Multicenter, Epidemiological Observational Study Centogene AG

2019: Principal Investigator- A Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP- 363856 in Subjects with Parkinson's Disease Psychosis Sunovion Pharmaceuticals

2019: Principal Investigator- A Phase 3, 4 Week, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel- Group Study of TD- 9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Parkinson's Disease Theravance Biopharma

2018- 2019: Principal Investigator-An Open-Label, 8-Week Study of Safety and Efficacy for Adjunctive Pimavanserin Treatment in Adults with Parkinson's Disease and inadequately Controlled Depression Acadia Pharmaceuticals

2018 - 2019: Principal Investigator-A Multicenter, Randomized, Double-Blind Placebo-Controlled Study with an Active-Treatment Dose- Blinded Period to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease Biogen

2018 - 2019: Principal Investigator-An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease Abbvie

2017 - 2019: Principal Investigator-A Phase 2A, Randomized, Double- Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy, of DA 9805 in Subject's with Parkinson's Disease Amarex

2017 - 2018: Sub-Investigator-A Phase 3 Multicenter, Randomized, Double- Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Aducanumab (8118037) in Subjects with Early Alzheimer' s Disease Biogen

2017 - 2019: Principal Investigator-A Randomized, Double-Blind, Placebo- Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability of Nilotinib Northwestern University

2017- 2019: Principal Investigator-A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects with Advanced Parkinson's Disease Neuroderm Ltd

2017-2019: Principal Investigator- The INSYTE Study, For the Management of Parkinson's Disease Psychosis in Actual Practice Acadia Pharmaceuticals 2

2017: Principal Investigator-A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off" Biotie Therapies

2016-2019: Principal Investigator-A Randomized, Double-Blind, Placebo- Controlled Trial of Urate-Elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease NINHS

2016-2018: Principal Investigator- RESTORE: A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy. Lundbeck

2016-2017: Principal Investigator- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson's Disease Impax Pharmaceuticals

2015-2017: Principal Investigator- Using Technology to Deliver Multi-Disciplinary Care to Individuals with Parkinson's Disease in Their Homes (Connect Parkinson.) National Parkinson Foundation

2014-2017: Principal Investigator-The National Parkinson's Foundation Patient Centered Questionnaire for Parkinson's Disease- English Language Validation National Parkinson Foundation

2013-2014: Principal Investigator-A Phase III 24 Week, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Add-On, Parallel- Group Study to Assess the Effect of Rasagiline on Cognition in Patients with Parkinson's Disease Teva Pharmaceuticals

2010-2013: Principal Investigator- Phase N DYSPORT for Injection Abotulinum toxin A Neurotoxin Clinical & Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD) Ipsen

2011-2012: Principal Investigator -Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Once- Weekly Oral Aripiprazole in Children and Adolescents with Tourette Disorder Otsuka

2007-2009: Principal Investigator- A Randomized, Double-Blind, Placebo- Controlled, Crossover Trial of High Dose versus Low Dose Carbidopa in Parkinson's Disease OHSU intramural support

2007-2009: Blinded Rater- Prospective Double-Blind Placebo-Controlled, Randomized, Multi-Center Trial with an Open-Label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Blepharospasm Merz Pharmaceuticals

1998-1999: Primary Researcher- Mental Illness and Neurological Disorders in Ancient Greece from the 8th through 2nd Century B CE College Scholars thesis with oral defense before faculty committee No financial support

FORENSICS

Case: Carly Guillory v. Taylor Mortlock et al., Retained by Plaintiff

Case: Young v. Providence Medical Center, Retained by Defense

Case: King County WA, Hoydal v. City of Bellevue, Retained by the Office of the Attorney General of WA

Case: Kootenai County, ID, Williams v. Northwest Specialty Hospital, Retained by Defense

Case: Cook County, IL, Smith v. Josselyn Center, et al, Retained by Plaintiff

Case: Spokane County, WA, Allbee v. Providence Medical Group Clinics, Retained by Defense.

Case: Walla Walla County, WA, Walla Walla Suites Motel, INC v. Jane Doe Williams, Retained by Defense.

Case: Spokane County, WA, Triplett v. WA State Dept of Social & Health Services, Retained by the Office of the Attorney General of WA.

Case: Sumter County, FL, Ben Ansley v. John Fennessy MD and Phoebe Physician Group, INC, Retained by Defense.

Case: King County, WA, Bussard v. Fannin Litigation Group, Retained by the Defense.

Case: King County, WA Dodge v. Evergreen School District No 114, Retained by Defense.

Case: Spokane County, WA, Pirrello v. Lanctot, Retained by Defense.

Case: Benton County, WA Cooper v. WA State Dept of Corrections, Retained by the Office of the Attorney General of WA

Case: Grant County, WA, Ratcliff v. Rimrock Meadows, Retained by Defense Case: Spokane County, WA, Cooper v. Sinha, Retained by Defense